Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 18 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Apalutamide Tablets, which are indicated for treating metastatic castration-sensitive prostate cancer. The tablets will be manufactured at Zydus Lifesciences Ltd's facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases